

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s):	Zang, Ying C.Q.	Art Unit:	TBD
App. No.:	10/575,831	Examiner:	TBD
Conf. No.:	2074	Title:	A METHOD FOR INCREASING CD8+ CYTOTOXIC T CELL RESPONSES AND FOR TREATING MULTIPLE SCLEROSIS
Int. Appl. No.:	PCT/US04/34448		
Int. Appl. Filing Date:	10/18/2004		

**Reply to Notification of Missing Requirements Under 35 U.S.C. § 371 in the United States Designated/Elected Office**

Dear Sir:

In response to the Notification of Missing Requirements Under 35 U.S.C. § 371 in the United States Designated/Elected Office mailed October 6, 2006 (the "Notification"), and accordance with the Rule of Practice, please consider the remarks below. Submitted herewith is a Petition for a two-month extension of time and the requisite fee of \$225.00 under 37 C.F.R. § 1.17(a), which extends the deadline for filing a response to February 6, 2007.

No other fees are believed to be due in connection with the filing of this paper, however, should any fees be deemed necessary, the Commissioner is hereby authorized to deduct any such fees from Deposit Account No. 50-1662 referencing the above-mentioned reference number.

**Amendments to the Specification** begin at page 2; **Remarks** begin at page 3.

## **AMENDMENTS TO THE SPECIFICATION**

Please make the following amendments to the specification.

After paragraph 0020 and before the heading, “Detailed Description,” please add the following heading and paragraph:

### **BRIEF DESCRIPTION OF THE SEQUENCE LISTING**

Reference is made to the appendix submitted herewith. The appendix contains the file “SequenceListing.txt” (2 KB), which was created February 5, 2007 and which is a Sequence Listing in accordance with 37 C.F.R. §§ 1.821-1.825, the contents of which are incorporated by reference herein.

## **REMARKS**

### **1. Amendments to the Specification**

The specification has been amended to direct entry of the substitute copy of the Sequence Listing via EFS-Web into the application in compliance with 37 C.F.R. §§ 1.821-1.825 and § 1.52(e)(5).

### **2. Oath or Declaration**

On page 1 of the Notification, the Patent Office requires an Oath/Declaration and surcharge to be furnished in order to complete the requirements for acceptance under 35 U.S.C. § 371. Applicant hereby submits:

1. a Declaration in compliance with 37 C.F.R. § 1.497(a); and
2. the requisite surcharge of \$65 in compliance with 37 C.F.R. § 1.27

to complete the requirements for acceptance under 35 U.S.C. § 371.

### **3. Sequence Listing**

On page 2 of the Notification, the Patent Office requires a substitute copy of the Sequence Listing in computer readable form. In lieu of filing a computer readable form, Applicant hereby submits a substitute copy of the Sequence Listing in electronic form via EFS-Web, which is identical to the Sequence Listing submitted with the application as filed. Accordingly, Applicant hereby states that no new matter has been added. Applicant respectfully submits that the Sequence Listing complies with 37 C.F.R. §§ 1.821-1.825.

#### **4. Conclusions**

Applicant submits that the application meets the requirements for acceptance under 35 U.S.C. § 371 and is ready for substantive examination.

Respectfully submitted,

POLSINELLI SHALTON FLANIGAN SUELTHAUS PC

Dated: February 5, 2007

By: /Paul Jenny/  
Paul Jenny  
Registration No.: 59014  
Customer No.: 27148

POLSINELLI SHALTON FLANIGAN SUELTHAUS PC  
180 N. Stetson Ave., Suite 4525  
Chicago, IL 60601  
312.873.3613 (direct)  
312.602.3955 (efax)